UNAIDS director proposes that President Trump make an ‘amazing deal’ to end HIV

GENEVA — The head of the United Nations’ AIDS agency said Monday that the sudden loss of American funding has been “devastating” for efforts to stop HIV and will cost the lives of many of the world’s most vulnerable people. But she also proposed an “amazing deal” for President Trump that she said could result in “the end of AIDS.”

At a news briefing in Geneva, UNAIDS Executive Director Winnie Byanyima said the deal would involve Trump enabling the U.S. company Gilead to produce and license its “magical” prevention drug lenacapavir across the world to the millions of people who need it.

Lenacapavir, sold as Sunlenca, has been shown through twice-yearly injections to completely prevent HIV infection in women and works nearly as well in men.

“President Trump likes deals,” Byanyima said, acknowledging that it was President George W. Bush who first started paying for the widespread rollout of HIV drugs more than two decades ago.

“It could be President Trump, another Republican president, who leads the prevention revolution towards the end of AIDS,” Byanyima said.

She added that the deal not only would result in profits for Gilead and create jobs for Americans, but also save millions of lives in poorer countries.

Byanyima said that American funding made up about 35% of UNAIDS’ core budget last year, but it was unclear whether that might be restored for next year. She said the agency was in talks with the U.S. government, but was also preparing for a worst-case scenario, in which there was no American funding available.

It was unlikely any other donors would be able to fill that vacuum, she said, adding that European donors have told the agency they would be cutting back on their support to redirect their funds to defense and other priorities.

Byanyima said that unless support to HIV efforts is restored, there could be more than 6.3 million additional deaths in the next four years and an additional 2,000 people per day becoming infected.

She acknowledged that there has been some valid criticism regarding how HIV aid has been delivered, calling it “an opportunity to rethink and develop more efficient ways of delivering lifesaving support.”

Byanyima also said that African countries were trying to become more self-sufficient and that even some of the poorest nations were now “trying to stretch very weak, fragile health systems to absorb people living with HIV.”